In the majority of patients, the presence of mutant DNMT3A in CR did not result in AML relapse, indicating that mutations in DNMT3A occur early on in leukemogenesis and that additional mutations in driver genes are required for the development of AML. This evidence concerns the gene DNMT3A and acute myeloid leukemia.